BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Y, Nepali K, Liou J. Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. J Med Chem 2017;60:527-53. [DOI: 10.1021/acs.jmedchem.6b00935] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Guiot J, Henket M, Frix A, Gester F, Thys M, Giltay L, Desir C, Moermans C, Njock M, Meunier P, Corhay J, Louis R. Combined obstructive airflow limitation associated with interstitial lung diseases (O-ILD): the bad phenotype ? Respir Res 2022;23. [DOI: 10.1186/s12931-022-02006-9] [Reference Citation Analysis]
2 Chen J, Peng Z, Lu M, Xiong X, Chen Z, Li Q, Cheng Z, Jiang D, Tao L, Hu G. Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy. Bioorganic & Medicinal Chemistry Letters 2018;28:222-9. [DOI: 10.1016/j.bmcl.2017.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Li X, Yue S, Luo Z. Mesenchymal stem cells in idiopathic pulmonary fibrosis. Oncotarget 2017;8:102600-16. [PMID: 29254275 DOI: 10.18632/oncotarget.18126] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
4 Wu H, Gu X, Li J, Wang M, Li Y, Yuan L, Wang J, Ma E. Identification of potential platelet-derived growth factor receptor α inhibitors by computational screening and binding simulations. J Mol Graph Model 2020;96:107527. [PMID: 31918319 DOI: 10.1016/j.jmgm.2019.107527] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Zhou S, Li W, Tian M, Zhang N, Yang X, Li W, Peng Y, Zheng J. Metabolic Activation of Pirfenidone Mediated by Cytochrome P450s and Sulfotransferases. J Med Chem 2020;63:8059-68. [DOI: 10.1021/acs.jmedchem.9b02073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Stenke E, Bourke B, Knaus U. Crohn's Strictures-Moving Away from the Knife.Front Pediatr. 2017;5:141. [PMID: 28670577 DOI: 10.3389/fped.2017.00141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
7 Kinoshita T, Goto T. Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review. Int J Mol Sci 2019;20:E1461. [PMID: 30909462 DOI: 10.3390/ijms20061461] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
8 Deng D, Pei H, Lan T, Zhu J, Tang M, Xue L, Yang Z, Zheng S, Ye H, Chen L. Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis. Eur J Med Chem 2020;185:111790. [PMID: 31699535 DOI: 10.1016/j.ejmech.2019.111790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Feng F, Zhang J, Wang Z, Wu Q, Zhou X. Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta-analysis. Exp Ther Med 2019;18:802-16. [PMID: 31258714 DOI: 10.3892/etm.2019.7579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
10 Wang J, Hu K, Cai X, Yang B, He Q, Wang J, Weng Q. Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sin B 2022;12:18-32. [PMID: 35127370 DOI: 10.1016/j.apsb.2021.07.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
11 Alsayed HA, Mohammad HMF, Khalil CM, El-Kherbetawy MK, Elaidy SM. Autophagy modulation by irbesartan mitigates the pulmonary fibrotic alterations in bleomycin challenged rats: Comparative study with rapamycin. Life Sci 2022;303:120662. [PMID: 35636582 DOI: 10.1016/j.lfs.2022.120662] [Reference Citation Analysis]
12 Juillerat-jeanneret L, Aubert J, Mikulic J, Golshayan D. Fibrogenic Disorders in Human Diseases: From Inflammation to Organ Dysfunction. J Med Chem 2018;61:9811-40. [DOI: 10.1021/acs.jmedchem.8b00294] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
13 Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, Park SW, Jeong SH, Park YB, Lee HL, Shin JW, Lee EJ, Lee JH, Jegal Y, Lee HK, Kim YH, Song JW, Park MS. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep 2018;8:4784. [PMID: 29555917 DOI: 10.1038/s41598-018-23073-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
14 Zhang R, Xu L, An X, Sui X, Lin S. Astragalus polysaccharides attenuate pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition and NF-κB pathway activation. Int J Mol Med 2020;46:331-9. [PMID: 32319542 DOI: 10.3892/ijmm.2020.4574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Estornut C, Milara J, Bayarri MA, Belhadj N, Cortijo J. Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis. Front Pharmacol 2022;12:794997. [DOI: 10.3389/fphar.2021.794997] [Reference Citation Analysis]
16 Yue L, Shi Y, Su X, Ouyang L, Wang G, Ye T. Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives. Eur J Med Chem 2021;224:113714. [PMID: 34315043 DOI: 10.1016/j.ejmech.2021.113714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Oglic D, Oatley SA, Macdonald SJF, Mcinally T, Garnett R, Hirst JD, Gärtner T. Active Search for Computer-aided Drug Design. Mol Inform 2018;37. [PMID: 29388736 DOI: 10.1002/minf.201700130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
18 Peng X, Li X, Li C, Yue S, Huang Y, Huang P, Cheng H, Zhou Y, Tang Y, Liu W, Feng D, Luo Z. NMDA receptor activation inhibits the protective effect of BM‑MSCs on bleomycin‑induced lung epithelial cell damage by inhibiting ERK signaling and the paracrine factor HGF. Int J Mol Med 2019;44:227-39. [PMID: 31115492 DOI: 10.3892/ijmm.2019.4195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Zhu D, Jiao Z, Chi YR, Gonçalves TP, Huang KW, Zhou JS. Asymmetric Three-Component Heck Arylation/Amination of Nonconjugated Cyclodienes. Angew Chem Int Ed Engl 2020;59:5341-5. [PMID: 31965664 DOI: 10.1002/anie.201915864] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
20 Mammoliti O, Jansen K, El Bkassiny S, Palisse A, Triballeau N, Bucher D, Allart B, Jaunet A, Tricarico G, De Wachter M, Menet C, Blanc J, Letfus V, Rupčić R, Šmehil M, Poljak T, Coornaert B, Sonck K, Duys I, Waeckel L, Lecru L, Marsais F, Jagerschmidt C, Auberval M, Pujuguet P, Oste L, Borgonovi M, Wakselman E, Christophe T, Houvenaghel N, Jans M, Heckmann B, Sanière L, Brys R. Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases. J Med Chem 2021;64:14557-86. [PMID: 34581584 DOI: 10.1021/acs.jmedchem.1c01066] [Reference Citation Analysis]
21 Dubey S, Dubey PK, Umeshappa CS, Ghebre YT, Krishnamurthy P. Inhibition of RUNX1 blocks the differentiation of lung fibroblasts to myofibroblasts. Journal Cellular Physiology. [DOI: 10.1002/jcp.30684] [Reference Citation Analysis]
22 Lei H, Cao Z, Wu H, Li T, Wang X, Chen Y, Ma E, Sun L, Zhai X. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model. Eur J Med Chem 2022;227:113951. [PMID: 34742015 DOI: 10.1016/j.ejmech.2021.113951] [Reference Citation Analysis]
23 Chen Y, Lei H, Li T, Cui Y, Wang X, Cao Z, Wu H, Zhai X. Design, synthesis and anti-fibrosis evaluation of imidazo[1,2-a]pyridine derivatives as potent ATX inhibitors. Bioorg Med Chem 2021;46:116362. [PMID: 34428714 DOI: 10.1016/j.bmc.2021.116362] [Reference Citation Analysis]
24 Paliogiannis P, Fois AG, Collu C, Bandinu A, Zinellu E, Carru C, Pirina P, Mangoni AA, Zinellu A. Oxidative stress-linked biomarkers in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Biomark Med 2018;12:1175-84. [PMID: 30191745 DOI: 10.2217/bmm-2018-0108] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
25 Bonifazi M, Di Vincenzo M, Caffarini M, Mei F, Salati M, Zuccatosta L, Refai M, Mattioli-Belmonte M, Gasparini S, Orciani M. How the Pathological Microenvironment Affects the Behavior of Mesenchymal Stem Cells in the Idiopathic Pulmonary Fibrosis. Int J Mol Sci 2020;21:E8140. [PMID: 33143370 DOI: 10.3390/ijms21218140] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Kaminskyy D, Kryshchyshyn A, Lesyk R. 5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry. Eur J Med Chem 2017;140:542-94. [PMID: 28987611 DOI: 10.1016/j.ejmech.2017.09.031] [Cited by in Crossref: 73] [Cited by in F6Publishing: 39] [Article Influence: 14.6] [Reference Citation Analysis]
27 Neumann E, Lepper N, Vasile M, Riccieri V, Peters M, Meier F, Hülser ML, Distler O, Gay S, Mahavadi P, Günther A, Roeb E, Frommer KW, Diller M, Müller-Ladner U. Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement. Cytokine 2019;117:41-9. [PMID: 30784899 DOI: 10.1016/j.cyto.2018.11.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Fois AG, Paliogiannis P, Sotgia S, Mangoni AA, Zinellu E, Pirina P, Carru C, Zinellu A. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review. Respir Res 2018;19:51. [PMID: 29587761 DOI: 10.1186/s12931-018-0754-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
29 Li T, Lei H, Yang J, Cao Z, Yang Y, Liu Z, Sun R, Yang X, Zhai X. Hybrid imidazo[1,2‐ a ]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect. Archiv der Pharmazie. [DOI: 10.1002/ardp.202200171] [Reference Citation Analysis]
30 Li L, Li Q, Wei L, Wang Z, Ma W, Liu F, Shen Y, Zhang S, Zhang X, Li H, Qian Y. Dexamethasone combined with berberine is an effective therapy for bleomycin-induced pulmonary fibrosis in rats. Exp Ther Med 2019;18:2385-92. [PMID: 31555349 DOI: 10.3892/etm.2019.7861] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Liu Z, Tang X, Zhu Z, Ma X, Zhou W, Guan W. Recent Advances in Fluorescence Imaging of Pulmonary Fibrosis in Animal Models. Front Mol Biosci 2021;8:773162. [PMID: 34796202 DOI: 10.3389/fmolb.2021.773162] [Reference Citation Analysis]
32 Yamauchi M, Barker TH, Gibbons DL, Kurie JM. The fibrotic tumor stroma. J Clin Invest 2018;128:16-25. [PMID: 29293090 DOI: 10.1172/JCI93554] [Cited by in Crossref: 92] [Cited by in F6Publishing: 52] [Article Influence: 23.0] [Reference Citation Analysis]
33 Liang Q, Cai W, Zhao Y, Xu H, Tang H, Chen D, Qian F, Sun L. Lycorine ameliorates bleomycin-induced pulmonary fibrosis via inhibiting NLRP3 inflammasome activation and pyroptosis. Pharmacological Research 2020;158:104884. [DOI: 10.1016/j.phrs.2020.104884] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
34 Magnini D, Montemurro G, Iovene B, Tagliaboschi L, Gerardi RE, Lo Greco E, Bruni T, Fabbrizzi A, Lombardi F, Richeldi L. Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration 2017;93:379-95. [DOI: 10.1159/000475780] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
35 Nwafor EO, Lu P, Liu Y, Peng H, Qin H, Zhang K, Ma Z, Xing B, Zhang Y, Li J, Liu Z. Active Components from Traditional Herbal Medicine for the Potential Therapeutics of Idiopathic Pulmonary Fibrosis: A Systemic Review. Am J Chin Med 2021;49:1093-114. [PMID: 34107859 DOI: 10.1142/S0192415X2150052X] [Reference Citation Analysis]
36 Liu X, Chen H, Su G, Song P, Jiang M, Gong J. An animal research and a chemical composition analysis of a Chinese prescription for pulmonary fibrosis: Yangfei Huoxue Decoction. Journal of Ethnopharmacology 2019;245:112126. [DOI: 10.1016/j.jep.2019.112126] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
37 Boxhammer E, Lehle K, Schmid C, von Suesskind-Schwendi M. Anti-oxidative effect of the tyrosine kinase inhibitor nintedanib: a potential therapy for chronic lung allograft dysfunction? Exp Lung Res 2020;46:128-45. [PMID: 32169022 DOI: 10.1080/01902148.2020.1738594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ma WH, Li M, Ma HF, Li W, Liu L, Yin Y, Zhou XM, Hou G. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci 2020;241:117139. [PMID: 31809714 DOI: 10.1016/j.lfs.2019.117139] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
39 Su X, Liu K, Xie Y, Zhang M, Wu X, Zhang Y, Wang J. Mushroom Inonotus sanghuang alleviates experimental pulmonary fibrosis: Implications for therapy of pulmonary fibrosis. Biomed Pharmacother 2021;133:110919. [PMID: 33202282 DOI: 10.1016/j.biopha.2020.110919] [Reference Citation Analysis]
40 Fang L, Cheng Q, Zhao F, Cheng H, Luo Y, Bao X, Li Y, Liang X, Huang Y, Xu J, Han J, Tang Y, Tang S, Liu W, Luo Z, Feng D. Cigarette smoke exposure combined with lipopolysaccharides induced pulmonary fibrosis in mice. Respiratory Physiology & Neurobiology 2019;266:9-17. [DOI: 10.1016/j.resp.2019.04.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
41 Shimizu H, Ito A, Sakurada K, Nakamura J, Tanaka K, Komatsu M, Takeda M, Saito K, Endo Y, Kozaki T, Shoda M, Kuriyama H. AK106-001616, a Potent and Selective Inhibitor of Cytosolic Phospholipase A2: In Vivo Efficacy for Inflammation, Neuropathic Pain, and Pulmonary Fibrosis. J Pharmacol Exp Ther 2019;369:511-22. [PMID: 30971478 DOI: 10.1124/jpet.118.255034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Nikolaou A, Ninou I, Kokotou MG, Kaffe E, Afantitis A, Aidinis V, Kokotos G. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. J Med Chem 2018;61:3697-711. [PMID: 29620892 DOI: 10.1021/acs.jmedchem.8b00232] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
43 Li X, Li C, Tang Y, Huang Y, Cheng Q, Huang X, Zhao F, Hao C, Feng D, Xu J, Han J, Tang S, Liu W, Yue S, Luo Z. NMDA receptor activation inhibits the antifibrotic effect of BM-MSCs on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2018;315:L404-21. [PMID: 29722562 DOI: 10.1152/ajplung.00002.2018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
44 Hettiarachchi SU, Li YH, Roy J, Zhang F, Puchulu-Campanella E, Lindeman SD, Srinivasarao M, Tsoyi K, Liang X, Ayaub EA, Nickerson-Nutter C, Rosas IO, Low PS. Targeted inhibition of PI3 kinase/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models. Sci Transl Med 2020;12:eaay3724. [PMID: 33115948 DOI: 10.1126/scitranslmed.aay3724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
45 Song X, Xu P, Meng C, Song C, Blackwell TS, Li R, Li H, Zhang J, Lv C. lncITPF Promotes Pulmonary Fibrosis by Targeting hnRNP-L Depending on Its Host Gene ITGBL1. Mol Ther 2019;27:380-93. [PMID: 30528088 DOI: 10.1016/j.ymthe.2018.08.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
46 Lei H, Li Z, Li T, Wu H, Yang J, Yang X, Yang Y, Jiang N, Zhai X. Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model. Bioorg Chem 2021;120:105590. [PMID: 34998121 DOI: 10.1016/j.bioorg.2021.105590] [Reference Citation Analysis]
47 Guan C, Qiao S, Lv Q, Cao N, Wang K, Dai Y, Wei Z. Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-γ and subsequent expression of HGF in colons. Toxicology and Applied Pharmacology 2018;343:1-15. [DOI: 10.1016/j.taap.2018.02.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
48 Qian W, Cai X, Qian Q, Zhang X. Identification and Validation of Potential Biomarkers and Pathways for Idiopathic Pulmonary Fibrosis by Comprehensive Bioinformatics Analysis. Biomed Res Int 2021;2021:5545312. [PMID: 34285914 DOI: 10.1155/2021/5545312] [Reference Citation Analysis]
49 Sun B, Liu X, Zheng X, Wang C, Meng Q, Sun H, Shu X, Liu K, Sun X, Li Y, Ma X. Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). ChemMedChem 2020;15:182-7. [PMID: 31755225 DOI: 10.1002/cmdc.201900606] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel) 2021;10:967. [PMID: 34208683 DOI: 10.3390/antiox10060967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Kou L, Kou P, Luo G, Wei S, Tejero J. Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis. Oxidative Medicine and Cellular Longevity 2022;2022:1-18. [DOI: 10.1155/2022/6197219] [Reference Citation Analysis]
52 Nagy MA, Hilgraf R, Mortensen DS, Elsner J, Norris S, Tikhe J, Yoon W, Paisner D, Delgado M, Erdman P, Haelewyn J, Khambatta G, Xu L, Romanow WJ, Condroski K, Bahmanyar S, McCarrick M, Benish B, Blease K, LeBrun L, Moghaddam MF, Apuy J, Canan SS, Bennett BL, Satoh Y. Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001. J Med Chem 2021;64:18193-208. [PMID: 34894681 DOI: 10.1021/acs.jmedchem.1c01716] [Reference Citation Analysis]
53 Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res 2018;19:32. [PMID: 29471816 DOI: 10.1186/s12931-018-0730-2] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 32.5] [Reference Citation Analysis]
54 Forte G, Bocca B, Pisano A, Collu C, Farace C, Sabalic A, Senofonte M, Fois AG, Mazzarello VL, Pirina P, Madeddu R. The levels of trace elements in sputum as biomarkers for idiopathic pulmonary fibrosis. Chemosphere 2021;271:129514. [PMID: 33434828 DOI: 10.1016/j.chemosphere.2020.129514] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Brennan EP, Cacace A, Godson C. Specialized pro-resolving mediators in renal fibrosis. Mol Aspects Med 2017;58:102-13. [PMID: 28479307 DOI: 10.1016/j.mam.2017.05.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
56 González-Gil I, Zian D, Vázquez-Villa H, Hernández-Torres G, Martínez RF, Khiar-Fernández N, Rivera R, Kihara Y, Devesa I, Mathivanan S, Del Valle CR, Zambrana-Infantes E, Puigdomenech M, Cincilla G, Sanchez-Martinez M, Rodríguez de Fonseca F, Ferrer-Montiel AV, Chun J, López-Vales R, López-Rodríguez ML, Ortega-Gutiérrez S. A Novel Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1), UCM-05194, Shows Efficacy in Neuropathic Pain Amelioration. J Med Chem 2020;63:2372-90. [PMID: 31790581 DOI: 10.1021/acs.jmedchem.9b01287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
57 Chang J, Nie H, Ge X, Du J, Liu W, Li X, Sun Y, Wei X, Xun Z, Li YC. Vitamin D suppresses bleomycin-induced pulmonary fibrosis by targeting the local renin-angiotensin system in the lung. Sci Rep 2021;11:16525. [PMID: 34400742 DOI: 10.1038/s41598-021-96152-7] [Reference Citation Analysis]
58 Yang M, Yin E, Xu Y, Liu Y, Li T, Dong Z, Tai W. CDKN2B antisense RNA 1 expression alleviates idiopathic pulmonary fibrosis by functioning as a competing endogenouse RNA through the miR-199a-5p/Sestrin-2 axis. Bioengineered 2022;13:7746-59. [PMID: 35291918 DOI: 10.1080/21655979.2022.2044252] [Reference Citation Analysis]
59 Beck H, Thaler T, Meibom D, Meininghaus M, Jörißen H, Dietz L, Terjung C, Bairlein M, von Bühler CJ, Anlauf S, Fürstner C, Stellfeld T, Schneider D, Gericke KM, Buyck T, Lovis K, Münster U, Anlahr J, Kersten E, Levilain G, Marossek V, Kast R. Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). J Med Chem 2020;63:11639-62. [PMID: 32969660 DOI: 10.1021/acs.jmedchem.0c00834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
60 Lin S, Zhang R, Xu L, Ma R, Xu L, Zhu L, Hu J, An X. LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1. Cell Death Dis 2020;11:706. [PMID: 32848140 DOI: 10.1038/s41419-020-02889-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
61 Al-Habeeb F, Aloufi N, Traboulsi H, Liu X, Nair P, Haston C, Azuelos I, Huang SK, White ES, Gallouzi IE, Di Marco S, Eidelman DH, Baglole CJ. Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production. J Cell Physiol 2021. [PMID: 33855709 DOI: 10.1002/jcp.30380] [Reference Citation Analysis]
62 Wang Y, Huang G, Wang Z, Qin H, Mo B, Wang C. Elongation factor-2 kinase acts downstream of p38 MAPK to regulate proliferation, apoptosis and autophagy in human lung fibroblasts. Exp Cell Res 2018;363:291-8. [PMID: 29355493 DOI: 10.1016/j.yexcr.2018.01.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
63 Sakai T, Takagaki H, Yamagiwa N, Ui M, Hatta S, Imai J. Effects of the Cytoplasm and Mitochondrial Specific Hydroxyl Radical Scavengers TA293 and mitoTA293 in Bleomycin-Induced Pulmonary Fibrosis Model Mice. Antioxidants (Basel) 2021;10:1398. [PMID: 34573030 DOI: 10.3390/antiox10091398] [Reference Citation Analysis]
64 Zhu D, Jiao Z, Chi YR, Gonçalves TP, Huang K, Zhou JS. Asymmetric Three‐Component Heck Arylation/Amination of Nonconjugated Cyclodienes. Angew Chem 2020;132:5379-83. [DOI: 10.1002/ange.201915864] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
65 Lin S, Jin J, Liu Y, Tian H, Zhang Y, Fu R, Zhang J, Wang M, Du T, Ji M, Wu D, Zhang K, Sheng L, Li Y, Chen X, Xu H. Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem 2019;62:8873-9. [DOI: 10.1021/acs.jmedchem.9b00969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
66 Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis. Front Pharmacol 2022;12:797292. [DOI: 10.3389/fphar.2021.797292] [Reference Citation Analysis]